Fig 2: Endometrial receptivity was significant restored by T10-UCMSCs vs. UCMSCs. (A-D)’ Immunohistochemical staining of vimentin in four groups. (A-D), 40x scare bar = 150 µm, (A’-D)’, 100x scare bar = 60µm. (E) The percentage of VEGF-positive areas was analyzed in the endometrium of four groups. F. The expression of HOXA10, ITGB3, and LIF in the endometrium was detected by western blot. (G-I) Statistic of (F). (J-L) The expression of HOXA10, ITGB3, and bFGF in the endometrium was detected by qRT-PCR. ***p<0.001, **p<0.01, *p<0.5, no significance (ns)

Fig 3: Establishment of T10-UCMSCs for endometrial injury transplantation. (A) The surface markers of umbilical cord mesenchymal stem cells (UCMSCs) (passage 2) were analyzed by flow cytometry. Antibodies against CD11, CD19, CD31, CD34, CD45, CD73, CD90 and CD105, and HLA-DR. (B) Percentage of positive cells in flow cytometry. (C, D) HOXA10 expression was confirmed by qRT-PCR and western blot analysis after lentiviral infection. (E) CCK8 assay of cell proliferation in the UCMSCs group, T10-UCMSCs, and UCMSCs groups with a lentiviral vector were used as controls. (F) The function of HOXA10 lentivirus was tested in vivo by dual-luciferase reporter gene assay, and the results demonstrated that HOXA10 exerted its effect by activating the downstream genes, Emx2 and ITGB3. ***p<0.001.

Fig 4: Characterisation of PL-EVs. (A–G) PL-EVs isolated from control subjects (n = 3): (A) Representative TEM images from UC and SEC + UF extraction. Thirty thousand (30K) and 100,000 (100 K) magnifications are shown, white arrows indicate some of the PL-EVs presented in the samples. (B) Quantification of the number of particles/mL. (C) Size (diameter, mean) of particles and (D) size distribution of particles determined by NTA. (E) Quantification of total protein cargo and (F) ratio of protein per particle. (G) Western blot results from a control subject for platelet marker (CD61), EV markers (ALIX, CD63, CD9), and non-EV components (ApoB, Albumin). The numbers corresponding to the SEC + UF represent the first four fractions collected. (H–L) PL-EVs isolated by UC from controls and mild and severe patients: (H) number of particles/mL and (I) size (diameter, mean) of particles measured by NTA (n = 5–6); (J) particle protein concentration (n = 4–5); (K) ratio of protein:particle (n = 4–5); and (L) size distribution of particles determined by NTA (n = 5–6). Plts, platelets; UC, ultracentrifugation method; SEC + UF, size exclusion chromatography + ultrafiltration method; ApoB, Apoprotein B; ALIX, ALG-2 interacting protein X.

Fig 5: MASTL expression correlates with ß3-integrin (ITGB3)-positive breast cancers(A) Immunohistochemical (IHC) staining of MASTL in breast cancer. ROI = region of interest.(B) Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression and amplification among MASTL-negative and -positive patients in the FinHer breast cancer trial series. The numbers refer to number of patients and the values in brackets are % of all patients.(C) Immunohistochemical (IHC) staining of MASTL in histologically normal human breast tissue: ROI = region of interest.(D) MASTL expression among ITGB3-negative and -positive patients in the FinHer breast cancer series.(E) Survival of FinHer patients with negative (ITGB3-), intermediate (ITGB3+), or high (ITGB3++) ITGB3 expression. Kaplan-Meier survival-table method and log rank test. See also Figure S1.